Sold as Cefadyl. Every FDA application for this active ingredient: 1 branded and 5 generic.
As of Nov 15, 2026, FDA lists 6 applications for Cephapirin Sodium (sold as Cefadyl), with 0 new uses approved and 0 published complete response letters.
| Mar 12, 1974 | CefadylANDA 61769 | Apothecon | 5 | Discontinued |
| Jul 2, 1987 | Cephapirin SodiumANDA 62720 | Hikma | 0 | Discontinued |
| — | Cephapirin SodiumANDA 62723 | Abraxis Pharm | 0 | Discontinued |
| — | CefadylANDA 62724 | Apothecon | 0 | Discontinued |
| — | CefadylANDA 62961 | Apothecon | 0 | Discontinued |
| — | CefadylNDA 50446 | Apothecon | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Apothecon
Hikma